Amgen to terminate participation in co-development and commercialization of brodalumab
Amgen announced it will terminate its participation in the co-development and commercialization of brodalumab with AstraZeneca. Brodalumab, an investigational IL-17 inhibitor, is in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. May 22, 2015